Insys Therapeutics (INSY) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Insys Therapeutics (NASDAQ:INSY) have been assigned an average recommendation of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $9.50.

INSY has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Cann reaffirmed an “average” rating on shares of Insys Therapeutics in a research note on Friday, March 2nd. ValuEngine raised shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 14th. Oppenheimer reaffirmed a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, March 11th. Finally, Piper Jaffray Companies cut shares of Insys Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Friday, March 9th.

Insys Therapeutics opened at $6.82 on Thursday, Marketbeat.com reports. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02. The stock has a market capitalization of $506.33 million, a PE ratio of -13.92 and a beta of 1.02.



Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). Insys Therapeutics had a negative return on equity of 43.27% and a negative net margin of 188.01%. The business had revenue of $23.90 million during the quarter, compared to the consensus estimate of $25.82 million. During the same quarter last year, the firm earned ($0.09) earnings per share. The business’s quarterly revenue was down 33.4% on a year-over-year basis. research analysts anticipate that Insys Therapeutics will post -0.91 earnings per share for the current year.

In related news, Director Brian Tambi sold 166,504 shares of Insys Therapeutics stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $6.41, for a total transaction of $1,067,290.64. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $25,640. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 65.40% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in INSY. ETF Managers Group LLC boosted its position in Insys Therapeutics by 130.2% in the 1st quarter. ETF Managers Group LLC now owns 649,898 shares of the specialty pharmaceutical company’s stock valued at $3,873,000 after buying an additional 367,630 shares during the period. Deutsche Bank AG boosted its position in Insys Therapeutics by 116.1% in the 4th quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock valued at $515,000 after buying an additional 28,923 shares during the period. JPMorgan Chase & Co. boosted its position in Insys Therapeutics by 303.5% in the 1st quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 19,273 shares during the period. Wells Fargo & Company MN boosted its position in Insys Therapeutics by 37.3% in the 4th quarter. Wells Fargo & Company MN now owns 57,020 shares of the specialty pharmaceutical company’s stock valued at $549,000 after buying an additional 15,504 shares during the period. Finally, Raymond James & Associates boosted its position in Insys Therapeutics by 93.5% in the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after buying an additional 14,982 shares during the period. 17.79% of the stock is owned by institutional investors.

About Insys Therapeutics

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply